https://www.selleckchem.com/pr....oducts/Mycophenolic-
Although latent tuberculosis infection (LTBI) treatment is given before anti-tumor necrosis factor (TNF) treatment, tuberculosis (T still develops in these patients and the risk factors are not well known. Besides, there is little data on the safety of isoniazid (INH) treatment in this group of patients. This study aimed to determine the risk factors for the development of tuberculosis and the safety of LTBI in such patients. All patients (n=665) given anti-TNF in a single center were included in this study. C
Curtir
Comentario
Compartilhar
